Serum tumor biomarkers such as CEA, NSE, and CYFRA 21-1 have been revealed to be associated with several clinical events in lung cancer, including diagnosis of tumor subtypes, prognosis, and detection of tumor recurrence, all of which are closely associated with tumor burden (24). This evidence concerns the gene CEACAM5 and lung cancer.